We report a case of toxic epidermal necrolysis in a 46-year-old woman on teriflunomide treatment. Such a severe adverse cutaneous drug reaction with this new therapy for relapsing forms of multiple sclerosis should be early recognized in order to ensure the rapid withdrawal of the drug.
O’ConnorPWolinskyJSConfavreuxC. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med2011; 365: 1293–1303.
2.
MillerAEWolinskyJSKapposL. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol2014; 13: 977–986.
3.
Bastuji-GarinSFouchardNBertocchiM. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol2000; 115: 149–153.
4.
SassolasBHaddadCMockenhauptM. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson Syndrome and toxic epidermal necrolysis: Comparison with case-control analysis. Clin Pharmacol Ther2010; 88: 60–68.
5.
de ProstNIngen-Housz-OroSDuongTA. Bacteremia in Stevens–Johnson syndrome and toxic epidermal necrolysis: Epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore)2010; 89: 28–36.
6.
HassikouHEl HaouriMTabacheF. Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis. Joint Bone Spine2008; 75: 597–599.
7.
RozmanB.Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet2002; 41: 421–430.
8.
Garcia-DovalILeCleachLBocquetH. Toxic epidermal necrolysis and Stevens–Johnson syndrome: Does early withdrawal of causative drugs decrease the risk of death?Arch Dermatol2000; 136: 323–327.
